Health ConditionsPremenstrual syndrome (PMS) encompasses clinically significant somatic and psychological manifestations during the luteal phase of the menstrual cycle, leading to substantial distress and impairment in functional capacity. These symptoms disappear within a few days of the onset of menstruation.
The symptoms of PMS usually cluster around the luteal phase of ovulation and resolve when menses begin or shortly thereafter. PMS symptoms can be both affective (e.g., anxiety, depression, irritability) and somatic (e.g., bloating, headache, swelling).
Symptoms of PMS include changes in appetite, weight gain, abdominal pain, back pain, low back pain, headache, swelling and tenderness of the breasts, nausea, constipation, anxiety, irritability, anger, fatigue, restlessness, mood swings, and crying.
Most women of reproductive age have some physical discomfort or dysphoria in the weeks before menstruation. Symptoms are often mild, but can be severe enough to substantially affect daily activities. About 5–8% of women thus suffer from severe premenstrual syndrome (PMS); most of these women also meet criteria for premenstrual dysphoric disorder (PMDD).
Premenstrual syndrome (PMS) is a common disorder affecting women of reproductive age, with an estimated global prevalence of 47.8%, with severe symptoms occurring in 3–8%, significantly affecting daily functioning.
The premenstrual dysphoric disorder (PMDD) is a more severe form of PMS, which has been included as a psychiatric disorder in the fifth edition of the Diagnostic and Statistical Manual for Mental Disorders (DSM-5). In PMDD, mood is markedly depressed, and anxiety, irritability, and emotional lability are pronounced. Suicidal thoughts may be present. Interest in daily activities is greatly decreased. In contrast to PMS, PMDD causes symptoms that are severe enough to interfere with routine daily activities or overall functioning.
The diagnosis of PMS is challenging due to the lack of explicit signs on physical examination and lack of diagnostic testing. For a definitive diagnosis, prospectively self-reported symptoms should demonstrate a cyclic pattern, and other psychological pathologies and thyroid dysfunction that may present with similar symptoms should be excluded.
Two main pathophysiological targets have been identified: one is the hypothalamus–pituitary–ovary axis, and the other targets brain serotonergic synapses. Fluctuations in gonadal hormone levels trigger the symptoms, and interventions that abolish ovarian cyclicity are effective.
Since PMS symptoms occur simultaneously with the hormonal fluctuations of the menstrual cycle, hormonal disproportion such as estrogen surplus and progesterone deficiency have been proposed as contributing factors. Estrogen levels that fluctuate during the luteal phase are responsible for women's mood changes.
The importance of serotonin for the regulation of mood and aggression, and the probable role of serotonin in modulating sex-steroid-driven behaviour, suggest that serotonin could be involved in the pathophysiology of PMS. A strong argument for the importance of serotonergic conduction is the lower peripheral blood serotonin levels during the luteal phase in women with PMS.
Progesterone suppresses estrogen receptors and increases monoamine oxidase (MAO) activity, lowering serotonin availability and resulting in a depressed mood.
The two best-studied and relevant neurotransmitter systems implicated in the genesis of symptoms are the GABAergic and the serotonergic systems. Metabolites of progesterone formed by the corpus luteum of the ovary and in the brain bind to a neurosteroid-binding site on the membrane of the GABA receptor, changing its configuration, rendering it resistant to further activation and finally decreasing central GABA-mediated inhibition.
GABA conductance and changes in neurosteroid levels, particularly allopregnanolone, are suspected to play a substantial role in the disorder's etiology.
Given the complex interplay between stress, immune responses, and hormonal regulation, HPA axis dysfunction may contribute significantly to the pathophysiology of PMS/PMDD, where both stress reactivity and immune system alterations synergistically worsen the disorder's symptoms.
CNS inflammation can affect the regulation of the HPO axis, HPA axis, the serotonin system, the GABAergic system, and brain-derived neurotrophic factor (BDNF), all of which have long been associated with the risk of PMS/PMDD.
Imaging studies provide evidence of altered GABA and serotonergic conduction in the amygdaloid nucleus and prefrontal cortex in patients affected by PMDD. Changes in mRNA expression of serotonin receptors 5-HT1A and 5-HT2A, GABAARs, and central monoamine neurotransmitter receptors were seen in the limbic system of a macaque model with PMS.
Recent research underscores the pivotal role of imbalances in TRYCATs—encompassing neurotoxic compounds like 3-HK and QUIN, as well as neuroprotective ones like KYNA—in the pathophysiology of mood disorders. Moreover, activation of the mucosal TRYCATs pathway is strongly associated with PMS, correlating with activation of IDO in mucosal tissues. The removal of tryptophan, the precursor of serotonin, from the diet induces premenstrual symptoms.
There is general agreement that all symptoms are triggered by fluctuations in sex steroids, and thus abolished when hormonal cyclicity ends. Importantly, research indicates that women with PMS do not have abnormal absolute hormone levels, but rather an abnormal sensitivity to normal cyclic hormonal changes. Although there is compelling evidence that progesterone plays a role in the pathophysiology of PMS, studies have shown that the classical progesterone receptor is not involved in this process, and many double-blind randomized controlled trials (RCTs) have failed to demonstrate the efficacy of progesterone supplementation.
A significant correlation was found between family history of PMS and psychological, physical, and behavioral symptoms of PMS. Multiple risk factors include age, weight, family history of PMS, marital status, smoking, herbal tea consumption, fast food consumption, and other dietary habits.
A BMI ≥27.5 was significantly associated with risk of PMS versus women with a BMI ≤20 over a 10-year follow-up period. Each 1 kg/m² increase in BMI was associated with a 3% increase in risk. BMI was also found to be most strongly related to physical and emotional symptoms including swelling of extremities, backache, abdominal cramping, food cravings, crying, mood swings, and irritability.
Since obesity is a modifiable risk factor, PMS management strategies should not only consider factors such as high stress and smoking but also obesity.
Depression, stress, sleep disturbance, and eating attitude problems have been known to influence PMS. Lifestyle factors including high stress levels, poor diet, lack of physical activity, and sleep disturbances were found to exacerbate symptoms.
Both PMS and PMDD were associated with poor physical health and psychological distress. Sociodemographic factors linked to a higher risk of PMS included advanced reproductive age, lower education level, and unemployment.
PMS is more likely to affect adults, especially those with poor physical health, high body mass index (BMI), or who suffer from amenorrhea, in addition to those with high levels of stress, a family history of depression, and/or postpartum depression.
Poor eating habits; sugar, alcohol, caffeine, and sodium intake; and stress have been implicated to some extent in the worsening of PMS symptoms. Vitamin and mineral deficiencies may also play a role, with calcium and certain B vitamins the most commonly referenced.
A large body of literature explores the relationship between various micronutrients, phytochemicals, and PMS. Sixty-two herbs, vitamins, and minerals have been identified for which claims of benefit for PMS were made, with RCT evidence found for only 10. Below, traditional use is clearly separated from scientific evidence for each major substance.
Calcium-rich foods and dairy were historically promoted for women's health in many European and North American folk traditions, though calcium was not historically articulated as a specific remedy for premenstrual complaints per se. Its formal investigation as a PMS intervention is a product of modern clinical medicine rather than ethnobotanical tradition.
Data supports the use of calcium for PMS, and only calcium had good quality evidence to support its use in PMS.
Serum calcium levels are reduced prior to the menstrual period, are lower in the luteal phase of the menstrual cycle than in the follicular phase, and this low level can exacerbate PMS symptoms by causing hallucinations, depression, and restlessness.
Treatment with vitamin B₆, calcium, and zinc consistently had significant positive effects on the psychological symptoms of PMS in a 2025 systematic review of 31 RCTs involving 3,254 participants. However, only 1 of the included studies had a low risk of bias, limiting the confidence of conclusions.
The American College of Obstetricians and Gynecologists (ACOG) recommends supplementation of 1,200 mg calcium daily to alleviate both physical and psychological PMS symptoms, especially reducing water retention and breast tenderness. The National Association for Premenstrual Syndromes (NAPS) suggests the daily use of 1 g calcium and 10 µg vitamin D3, especially for migraine treatment.
Evidence strength: Moderate-to-good. Calcium is the most consistently supported natural supplement in systematic reviews for PMS, though many individual trials are small.
Magnesium-containing mineral waters and preparations were used in traditional European medicine for nervous complaints and muscle tension, though not specifically for PMS as a named condition. Its role in PMS research is again primarily a modern clinical pursuit.
There is evidence of benefit for calcium and vitamin B₆ in women with premenstrual syndrome, mixed findings for magnesium and evening primrose oil, and insufficient data about St. John's Wort, agnus castus, or ginkgo biloba according to a systematic review in the DARE database.
The findings of a randomized clinical trial indicated that magnesium plus vitamin B₆ had the greatest effect on mean PMS score compared with placebo. However, the same systematic review noted no evidence of benefit with magnesium oxide. The form of magnesium supplemented (oxide versus pyrrolidone versus glycinate) appears relevant to outcomes, as different forms show different bioavailability.
There was insufficient evidence to support the effects of magnesium on psychological PMS symptoms in the 2025 systematic review of 31 RCTs.
Evidence strength: Mixed and form-dependent. Some RCTs show benefit for magnesium pyrrolidone; magnesium oxide has not demonstrated benefit. Overall evidence remains preliminary.
Vitamin B₆ came to be associated with PMS primarily through mid-20th century clinical interest in its role in estrogen metabolism and neurotransmitter synthesis, rather than through deep historical ethnobotanical tradition.
The Royal College of Obstetricians and Gynecologists, as first-line treatment for PMDD, recommends vitamin B₆ supplementation, despite the low level of evidence for its effectiveness. The NAPS recommend vitamin B₆ for treating mild-to-moderate PMS, with a maximum daily intake of 50 mg under the supervision of a primary care physician. However, available evidence supporting its efficacy remains insufficient.
Data suggests that vitamin B₆ may be effective for PMS, though methodological limitations across trials make firm conclusions difficult. High B₆ doses may promote the development of peripheral neuropathy.
Treatment with vitamin B₆, calcium, and zinc consistently had significant positive effects on the psychological symptoms of PMS across the 2025 systematic review of 31 RCTs.
Evidence strength: Suggestive but limited. Guideline bodies acknowledge potential benefit at moderate doses, while systematic reviews rate the overall evidence quality as low.
Vitamin D has no traditional ethnobotanical role in PMS. Research into this association is entirely a product of contemporary nutritional science.
Case-control studies have investigated the association between the risk of premenstrual syndrome and vitamin D, calcium, and magnesium status among university students. A 2019 randomized clinical trial found that in the vitamin D group, serum levels of IL-10 and IL-12 significantly decreased while total antioxidant capacity (TAC) significantly increased post-intervention, with significant differences in serum IL-12 and TAC levels between the two groups.
There was insufficient evidence to support the effects of vitamin D on psychological PMS symptoms in the 2025 systematic review.
Evidence strength: Preliminary. Individual RCTs show effects on inflammatory markers, but systematic review-level evidence is insufficient to draw definitive conclusions.
Zinc-rich foods such as oysters, seeds, and pulses have long been noted in many traditional food systems for supporting reproductive health, although specific use of zinc as a PMS intervention is a modern clinical concept.
Treatment with vitamin B₆, calcium, and zinc consistently had significant positive effects on the psychological symptoms of PMS across the 2025 systematic review of 31 RCTs involving 3,254 participants. A randomized, double-blind, placebo-controlled trial specifically studied the effect of zinc supplementation on quality of life and sleep quality in young women with premenstrual syndrome.
Evidence strength: Emerging positive signal in the systematic review context, though fewer studies exist for zinc than for calcium or B₆.
Consumption of fish and fish oils has been embedded in the diets of many coastal and northern populations (Nordic, Japanese, Inuit) for centuries, with these foods broadly associated with good health. No specific traditional use for PMS as a clinical entity has been documented in historical ethnobotanical sources.
The treatment of premenstrual symptoms using omega-3 supplement reduced symptoms and ameliorated women's quality of life, according to one randomized clinical trial. A pilot RCT evaluated the effect of omega-3 fatty acids on PMS treatment using a randomized double-blind controlled trial performed on 184 eligible women randomly assigned to two groups; in the omega-3 group, 2 g of omega-3 was prescribed daily (two 1 g pearls), and in the control group, matching placebo soft gels were prescribed.
Studies published so far showed that low intake of fats and high intake of fresh, unprocessed foods rich in omega-3 fatty acids may help prevent the onset of PMS and reduce the severity of its symptoms.
Evidence strength: Preliminary positive. Individual RCTs are encouraging but the evidence base remains limited in size and methodological rigor. Omega-3 supplementation is among the better-researched candidates after calcium.
Vitex agnus castus (VAC), also known as chaste tree, is a plant from the Mediterranean area, Crimea, and central Asia. Its fruit has been used for more than 2,500 years as a phytotherapeutic agent. In the last century, VAC has been mostly used for the treatment of premenstrual syndrome, menstrual irregularities, fertility disorders, and symptoms of menopause.
In older European traditions, vitex was associated with women's reproductive health, menstrual comfort, and cyclical breast pain. The plant produces small dark fruits that look somewhat like peppercorns, and these fruits are the medicinal material used in teas, tinctures, capsules, and standardized extracts.
The mechanism of action appears to be agonistic activity on pituitary dopamine D2 receptors that inhibit the secretion of prolactin from the lactotrope cells, with additional pharmacological actions through opioid receptors. Physiological results include a relative decrease in FSH, a relative increase in LH, an inhibition of prolactin, a relative increase in progesterone, and a normalizing of the luteal phase of the menstrual cycle.
Pre-clinical studies suggest that extracts prepared from the fruits of Vitex agnus castus interact with dopamine D2 receptors, leading to reduced prolactin secretion. Diterpenes featuring a clerodadienol scaffold were identified as major active compounds, but no conclusive data regarding their potency and intrinsic activity are available.
Researchers found 17 randomized controlled trials of Vitex agnus castus in the treatment of premenstrual syndrome, 14 of which could be included in a quantitative (meta-)analysis. All trials, except one, found the Vitex agnus castus preparation to be more efficacious than placebo, pyridoxine, and magnesium for either total symptom score or individual symptoms or symptom clusters. Unfortunately, the majority of trials is hampered by a high risk of bias.
The remission of symptoms was 2.57 times more likely in those taking VAC than in those who received a placebo in one meta-analysis of double-blind RCTs. However, although meta-analysis shows a large pooled effect of VAC in placebo-controlled trials, the high risk of bias, high heterogeneity, and risk of publication bias of the included studies preclude a definitive conclusion. The pooled treatment effects should be viewed as merely explorative and, at best, overestimating the real treatment effect of VAC for PMS symptomatology.
All eight studies included in one systematic review were positive for VAC in the treatment of PMS or PMDD and VAC was overall well tolerated. Main limitations were differences in definition of diagnostic criteria, the instruments used as main outcome measures, and different preparations of VAC extracts limiting the comparison of results between studies. Nevertheless, the RCTs using VAC for treatment of PMS/PMDD suggested that the VAC extract is a safe and efficacious alternative to be considered for the treatment of PMS/PMDD symptoms.
In one study, patients with PMDD were treated with fluoxetine and Vitex agnus-castus. Fluoxetine helped to treat psychological symptoms while the VAC extract reduced the physical symptoms.
Evidence strength: Moderate, with caveats. Multiple systematic reviews find positive effects, but high risk of bias, heterogeneity, and lack of standardized extract preparations limit definitive conclusions. VAC has more clinical trial support than most other botanicals used for PMS.
Evening primrose (Oenothera biennis) is native to North America, where indigenous peoples used various parts of the plant for different ailments. Its oil extracted from seeds became widely used in European herbal and nutritional medicine from the 1970s onward for a range of women's health conditions, including PMS and cyclical breast pain.
Evening primrose oil contains two types of omega-6 fatty acids including linoleic acid (60–80%) and γ-linolenic acid (8–14%).
A systematic literature search of clinical trials of evening primrose oil for the treatment of PMS found only seven placebo-controlled trials, but only in five trials was randomization clearly indicated. Inconsistent scoring and response criteria made statistical pooling and hence a rigorous meta-analysis inappropriate. The two most well-controlled studies failed to show any beneficial effects for EPO, although because the trials were relatively small, modest effects cannot be excluded. On current evidence, EPO is of little value in the management of premenstrual syndrome.
There was no statistically significant evidence of effectiveness for evening primrose oil (three RCTs, two good quality). The only best finding of one meta-analysis article is the safety of 3 to 6 g daily dose of evening primrose oil in volunteers with PMS.
Evidence strength: Weak. Despite widespread traditional use, well-controlled clinical trials have not demonstrated benefit for PMS, and evening primrose oil is not supported by current systematic evidence.
Saffron has been used for over 3,000 years in Persia, the Mediterranean, and South Asia as a culinary spice, dye, and medicinal agent. In Unani (Greco-Arabic) medicine and traditional Persian medicine, saffron was used for mood-related and menstrual complaints, among many other applications.
Preliminary data shows some benefit with saffron in the treatment of PMS, according to a 2009 systematic review of RCTs. RCTs on Unani medicinal plants such as Crocus sativus (saffron/zafran) have been included in systematic analyses of herbal approaches to PMS. Saffron's active constituents—crocin, crocetin, and safranal—are hypothesized to modulate serotonin and dopamine pathways.
Evidence strength: Preliminary. A small number of RCTs report positive findings, but the evidence base is insufficient for firm recommendations.
Ginkgo biloba has been used in traditional Chinese medicine for several thousand years, primarily for cognitive function, circulation, and respiratory complaints. Its use for PMS or menstrual disorders is not a primary traditional application but has been explored in more recent clinical research.
Preliminary data shows some benefit with ginkgo for PMS. Ginkgo's bioflavonoids have anti-inflammatory activity, as they inhibit cyclooxygenase and lipoxygenase (important for the production of inflammatory prostaglandins) and are stress modulators. In addition, the quercetin bioactive molecule present in ginkgo is a potent inhibitor of histamine release. Hence, one research team concluded that ginkgo was able to reduce the severity of PMS symptoms through this mechanism.
There is insufficient data about ginkgo biloba in systematic reviews covering PMS interventions.
Evidence strength: Preliminary and limited. Only a small number of trials exist; not supported by strong systematic evidence for PMS.
St. John's Wort has a long history of use in European herbal medicine going back at least to ancient Greece, primarily for nerve pain and depressive complaints. Its application for PMS grew from its well-documented use for mild-to-moderate depression.
Preliminary data shows some benefit with St. John's Wort for PMS. However, there was no statistically significant evidence of effectiveness for St. John's Wort (one good-quality RCT).
Evidence strength: Insufficient. While its antidepressant mechanisms (serotonin reuptake inhibition, among others) provide a biological rationale, the RCT evidence specific to PMS is limited and not statistically significant in current reviews.
Foods naturally rich in tryptophan (turkey, dairy, seeds, legumes) have not been specifically associated with PMS management in pre-modern herbal traditions; this is a modern nutritional science hypothesis.
Clinical trials have shown that serotonin precursors significantly increase between days 7 to 11 and 17 to 19 of the menstrual cycle, indicating that PMS is closely associated with mood disorders through estrogen–serotonin regulation. The removal of tryptophan, the precursor of serotonin, from the diet induces premenstrual symptoms.
Evidence strength: Mechanistically plausible and supported by challenge studies (tryptophan depletion reliably worsens symptoms), but direct supplementation studies for PMS are limited.
Studies published so far showed that low intake of simple carbohydrates, fats, salt, and alcohol, and high intake of fresh, unprocessed foods rich in B vitamins, vitamin D, zinc, calcium, and omega-3 fatty acids may help prevent the onset of PMS and reduce the severity of its symptoms. However, further studies are needed to formulate definitive recommendations for the use of vitamins, micronutrients, and other dietary ingredients in women with PMS to improve functioning. Large, randomized, double-blind clinical trials across diverse populations are necessary to formulate clear recommendations.
Poor eating habits; sugar, alcohol, caffeine, and sodium intake; and even stress have been implicated to some extent in the worsening of PMS symptoms. Reduction in caffeine intake is included in standard non-pharmacological management guidance, though rigorous RCT evidence specifically isolating these dietary components for PMS is limited.
Non-pharmacological management of PMS includes, among other approaches, increased calcium and carbohydrate intake. Complex carbohydrates are hypothesized to transiently raise serotonin availability via an insulin-mediated tryptophan uptake mechanism, though there was insufficient evidence to support the effects of whole-grain carbohydrates on psychological PMS symptoms in the 2025 systematic review of 31 RCTs.
Physical activity and exercise are among the various non-pharmacological therapies used to treat mild PMS symptoms. Lifestyle factors including high stress levels, poor diet, lack of physical activity, and sleep disturbances were found to exacerbate symptoms. Aerobic exercise is incorporated in most non-pharmacological PMS management guidelines based on accumulated observational and clinical data, though effect size estimates vary across individual studies.
Emotional factors (i.e., depression and stress) and lifestyle factors (i.e., sleep, diet, and exercise) have been identified as determinants of PMS in studies of female college students. Sleep disturbance both exacerbates and may be caused by PMS, forming a bidirectional relationship between cycle-dependent symptom burden and sleep quality.
Study findings show a significant positive association between milk product consumption and the severity of PMS symptoms. Globally, between 20% and 32% of premenopausal women and 30–40% of women of reproductive age reported having PMS during their menstrual cycle. The relationship between dairy and PMS is complex: dairy is a major source of dietary calcium, which is associated with symptom reduction, yet some research suggests that excessive dairy may also influence hormonal signaling.
Observational evidence from prospectively followed cohorts suggests that higher dietary intake of non-heme iron (from plant sources) is associated with reduced PMS risk. Iron's involvement in serotonin synthesis has been proposed as a mechanistic explanation, though direct RCT evidence specific to PMS is limited.
Preliminary data shows some benefit with soy for PMS, while there was insufficient evidence to support the effects of soy isoflavones on psychological PMS symptoms in the most recent systematic review. Overall, the evidence for soy and its isoflavones specific to PMS remains inconclusive.
The Mayo Clinic highlights the supplementation of calcium, magnesium, vitamin E, vitamin B₆, and herbal remedies but underscores the lack of conclusive evidence supporting their effectiveness. Further research is needed using RCTs of adequate length, sufficient sample size, well-characterized products, and measuring the effect on severity of individual PMS symptoms.
5-HTP is the immediate precursor to serotonin, and reduced serotonergic activity is well-documented in women with PMS and PMDD. PET imaging studies confirm abnormal 5-HTP-derived serotonin activity in prefrontal cortices of women with premenstrual dysphoria. Systematic review evidence indicates 5-HTP is better than placebo for alleviating menstrual depression.
Calcium has the strongest evidence base among all supplements for PMS. A landmark RCT of 720 women showed 1,200 mg/day calcium carbonate produced a 48% overall reduction in PMS symptom scores versus placebo over three months. Multiple systematic reviews confirm calcium as the only natural product with consistently high-quality evidence for PMS.
Chamomile exhibits calming, sedative, and anti-inflammatory effects relevant to PMS, and was a component of the PMSoff supplement that significantly reduced PMS symptoms in a 2025 double-blind RCT. Traditional use for menstrual discomfort and anxiety is long-established across European and Middle Eastern herbal medicine.
Chaste Tree (Vitex agnus-castus) is approved by German health authorities for PMS and premenstrual mastodynia. Meta-analysis of three double-blind RCTs found women taking chaste tree were 2.57 times more likely to achieve PMS symptom remission versus placebo. Eight qualifying RCTs all showed positive results.
Curcumin, the principal bioactive of turmeric, has been evaluated in multiple RCTs for PMS and dysmenorrhea, with a 2025 systematic review of 10 RCTs finding that 6 reported significant PMS symptom improvement. Curcumin inhibits COX-2 and prostaglandin production and modulates inflammatory biomarkers and vitamin D status in PMS patients.
EPA-containing omega-3 supplementation has been studied for premenstrual syndrome (PMS), with evidence suggesting reductions in mood-related and physical symptoms via anti-inflammatory prostaglandin modulation. Krill oil (high in EPA+DHA) RCTs show reduced emotional symptoms and pain compared to placebo in PMS.
Evening primrose oil has been evaluated in multiple RCTs for PMS with mixed to negative findings. The 2009 Whelan systematic review found no evidence of benefit with evening primrose oil for PMS, while the DARE systematic review found mixed findings. It remains widely used traditionally despite inconclusive clinical trial evidence.
Multiple clinical trials have examined fennel for PMS symptom severity. Studies demonstrate statistically significant reductions in PMS severity scores with fennel extract vs. control groups. The effect appears consistent across studies including a randomized clinical trial in university students and a study comparing fennel with exercise.
Fenugreek has demonstrated clinical benefit for primary dysmenorrhea (painful menstruation)—a core PMS symptom—in a double-blind RCT showing significant pain reduction and improvement in associated systemic symptoms. Its anti-inflammatory and antispasmodic properties, along with phytoestrogenic action, are the proposed mechanisms.
A clinical trial of geranium aromatherapy massage demonstrated significant reduction in PMS symptoms. Geranium is proposed to stimulate the adrenal cortex and support hormonal balance. It has documented use for PMS-related emotional and physical symptoms in both clinical and traditional settings.
Ginger is listed among botanical supplements studied for PMS, and RCTs of ginger for dysmenorrhea (menstrual cramping, a core PMS symptom) show significant pain reduction. Multiple RCTs find ginger comparable to ibuprofen and mefenamic acid for dysmenorrhea pain, and it is listed among herbs used for PMS in authoritative botanical reviews.
Ginkgo biloba extract has been evaluated in RCTs for PMS, with studies finding reductions in congestive and mood-related PMS symptoms. A 2009 RCT using standardised EGb 761 extract administered from day 16 of the cycle through day 5 of the next cycle showed significant reductions in PMS symptom severity versus placebo.
The evidence for inositol in PMS/PMDD is mixed. A 2011 RCT (Carlomagno et al., Human Psychopharmacology) demonstrated efficacy of a new myo-inositol formulation in PMDD. However, an earlier 2002 small crossover RCT found no benefit, and a 2014 meta-analysis showed only a non-significant trend toward benefit for PMDD-related depressive symptoms. The phosphatidylinositol second messenger system provides a plausible mechanistic rationale.
Isoflavones as a class (including soy isoflavones) are phytoestrogens documented to show preliminary RCT evidence for PMS benefit in systematic reviews. They act as selective estrogen receptor modulators, modulating the hormonal environment of the menstrual cycle.
The Sampalis et al. (2003) double-blind RCT (n=70 women) found Neptune Krill Oil significantly improved both physical and emotional symptoms of PMS versus baseline, with improvements greater than the fish oil comparator. A 3-month pilot with 29 women using a krill oil-based formulation also showed significant reductions in PMS symptoms.
L-tryptophan is the dietary amino acid precursor to 5-HTP and ultimately serotonin, providing the upstream substrate for the serotonin pathway implicated in PMS. Tryptophan depletion studies worsen PMS mood symptoms, and L-tryptophan supplementation has been studied for PMDD-related depression and irritability.
Lavender aromatherapy has been evaluated in RCTs specifically for PMS and found to reduce psychological and physical symptoms. Lavender appeared in the PMSoff RCT combination supplement that significantly reduced PMS symptoms in a 2025 double-blind trial. Lavender's linalool and linalyl acetate have documented anxiolytic and analgesic properties.
Authoritative sources note that clinical trials of licorice-containing herbal combinations showed benefit in dysmenorrhea and PMS. Licorice isoflavones may inhibit serotonin reuptake, potentially addressing mood-related PMS symptoms. Phytoestrogenic compounds may modulate the hormonal fluctuations underlying PMS.
Magnesium deficiency has been implicated in PMS pathophysiology, with studies showing lower red blood cell magnesium in PMS patients. RCTs using magnesium pyrrolidone show preliminary benefit for premenstrual mood and fluid retention symptoms. A synergistic effect with vitamin B6 has been documented in a double-blind crossover RCT for anxiety-related PMS symptoms.
A controlled metabolic trial found that low dietary manganese was associated with increased mood and pain symptoms during the premenstrual phase. A PMC review identifies manganese among minerals potentially involved in PMS pathophysiology, though only one study with combined manganese/calcium exposure exists.
Omega-3 fatty acids (EPA/DHA) reduce production of pro-inflammatory prostaglandins that drive menstrual pain and PMS symptoms. A randomised double-blind trial in 184 women showed omega-3 supplementation reduced psychiatric and somatic PMS symptoms including depression, nervousness, anxiety, bloating, and headache. A systematic review with meta-analysis confirms anti-dysmenorrhea effects.
Phytoestrogens as a class—including soy isoflavones and red clover isoflavones—bind estrogen receptors and modulate the hormonal environment of PMS. They are listed among natural interventions studied for PMS management in systematic reviews and used in traditional and complementary medicine.
Clinical evidence supports Pycnogenol for relief of premenstrual symptoms including abdominal pain. A review of clinical pharmacology noted PYC relieves premenstrual symptoms including abdominal pain via spasmolytic action of phenolic acids. The menstrual cramp RCTs also enrolled women with PMS-type symptoms.
PMS is linked to the progesterone decline in the late luteal phase and to GABA-A receptor sensitivity to progesterone's metabolite allopregnanolone. The Cochrane-registered review of progesterone for PMS found insufficient evidence that oral or vaginal progesterone alone is superior to placebo, but the GABA-A neurosteroid mechanism linking progesterone fluctuations to PMS symptoms is well established.
A systematic review and meta-analysis of RCTs found Rosa damascena reduces menstruation-related headache, fatigue, anxiety, and bloating—core PMS symptoms. Multiple RCTs using aromatherapy and oral extract support this evidence. Traditional use of rose for PMS is well-documented in Persian medicine.
Saffron (Crocus sativus) has been evaluated in multiple RCTs for PMS and PMDD. Its bioactive compounds crocin and safranal inhibit reuptake of serotonin, dopamine, and norepinephrine. A double-blind RCT showed saffron was non-inferior to fluoxetine for PMDD; a systematic review confirmed positive effects on PMS mood and psychological symptoms.
Soy isoflavones have been included among products showing preliminary RCT evidence for PMS benefit in a 2009 systematic review. Isoflavones bind estrogen receptors and may modulate hormonal fluctuations contributing to PMS; one RCT found soy consumption reduced affective PMS symptoms versus placebo.
Soy isoflavones are the phytoestrogenic compounds responsible for soy's effects on PMS. Isoflavones genistein and daidzein bind estrogen receptors with SERM-like activity and may modulate the hormonal environment of PMS. RCT evidence is preliminary but present in systematic reviews.
Spirulina was a component of the PMSoff combination supplement that demonstrated significant PMS symptom reduction in a 2025 double-blind RCT. Spirulina has documented anti-inflammatory and antioxidant properties proposed to alleviate PMS-related symptoms. It is a nutrient-dense blue-green algae used in women's reproductive health contexts.
St. John's Wort (Hypericum perforatum) was tested in a double-blind, placebo-controlled crossover RCT in 36 women with mild PMS and was statistically superior to placebo for physical and behavioural PMS symptoms. Multiple systematic reviews include it among products with preliminary evidence for PMS benefit.
Valerian has sedative and GABAergic properties relevant to PMS-related insomnia and anxiety. An RCT evaluating valerian capsules for premenstrual mood and behavioural symptoms found a significant decrease in symptom severity. Valerian also appeared in the PMSoff combination RCT which demonstrated significant PMS benefit.
Vitamin B1 (thiamine) has been associated with improved mood and reduced anxiety in PMS, and appeared in the PMSoff combination supplement that showed significant PMS symptom reduction in a 2025 double-blind RCT. Observational data also link higher thiamine intake with lower PMS risk. Thiamine is also listed among nutritional supplements reported effective for dysmenorrhea.
Vitamin B6 is a cofactor in serotonin and dopamine synthesis, both relevant to PMS pathophysiology. A systematic review covering 25 studies found pooled evidence of benefit for vitamin B6 in PMS, though findings were mixed across individual trials. German Commission E and systematic reviews support its use, particularly for premenstrual depression.
Low vitamin D levels are associated with increased PMS risk and severity; PMS has been characterised as a calcium/vitamin D deficiency state that is unmasked during the luteal phase. RCTs of combined calcium and vitamin D show significant PMS symptom reduction, and a high-dose vitamin D3 trial showed reductions in PMS incidence.
Vitamin E has shown preliminary benefit for PMS in RCTs, particularly for mood and physical symptoms. The 2009 Whelan systematic review identified vitamin E among products with preliminary RCT evidence for PMS benefit. A combined vitamin D and E RCT (2024) showed significant PMS score reduction in vitamin D-deficient women.
Vitex agnus-castus (chasteberry) has been approved by German health authorities for PMS, breast tenderness, and menstrual irregularity. A 2020 meta-analysis of three double-blind RCTs found women taking VAC extracts were 2.57 times more likely to experience PMS symptom remission versus placebo. A 2017 systematic review identified 8 qualifying RCTs, all positive for VAC in PMS or PMDD.
A controlled study in 334 female students showed yarrow extract significantly reduced overall PMS symptom scores and pain severity versus placebo over three months. This constitutes direct clinical evidence for yarrow in premenstrual syndrome.
Agnuside is an iridoid glycoside and one of the marker compounds of Vitex agnus-castus (chasteberry). It contributes to the standardisation of chasteberry extracts used in PMS clinical trials and is considered a marker constituent of preparations with documented PMS efficacy.
Asparagus racemosus is traditionally used in Ayurvedic medicine to support female reproductive health, including for premenstrual complaints. Preclinical and limited clinical data support its hormonal modulating properties. No dedicated PMS RCT has been published.
Black cohosh has a documented traditional use for PMS and premenstrual mood and physical symptoms spanning Native American and 19th-century American practice. The NCCIH lists PMS as a promoted indication. Modern clinical trials targeting PMS specifically are very sparse, small, and inconclusive.
Borage oil has a documented traditional use for premenstrual syndrome, attributed to GLA's role in prostaglandin modulation, which may reduce breast tenderness, bloating, irritability, and cramping. Small studies suggest benefit but systematic reviews find insufficient high-quality evidence specific to borage oil.
Borage oil is widely used traditionally to relieve PMS symptoms including breast tenderness, cramping, mood changes, and fluid retention, attributed to GLA's ability to support prostaglandin E1 synthesis and modulate prolactin-related effects. Clinical evidence is primarily from EPO trials and not borage oil specifically; evidence for borage oil in PMS from RCTs is lacking.
In TCM, B. falcatum is a central herb for Liver Qi stagnation, a pattern that corresponds closely to PMS symptoms: irritability, mood swings, bloating, and cramping. It is the primary constituent of Jia Wei Xiao Yao San, historically used for premenstrual emotional disturbances. No isolated human clinical trials for PMS specifically with B. falcatum alone have been identified.
Casticin is a polymethoxylated flavone constituent of Vitex agnus-castus fruit, one of the bioactive compounds in chasteberry extracts used for PMS. It has documented anti-inflammatory and anti-proliferative properties in preclinical studies, contributing to the overall mechanism of action of Vitex preparations for PMS.
Cramp bark (Viburnum opulus) is used in traditional Western herbalism as a uterine antispasmodic and analgesic for menstrual cramps associated with PMS. Animal studies and human uterine tissue experiments suggest antispasmodic effects, but no PMS-specific placebo-controlled clinical trials have been performed.
Damiana is traditionally used in Latin American and European herbal medicine for premenstrual symptoms including irritability, nervous tension, and pelvic discomfort. Its nervine, antispasmodic, and mild phytoestrogenic actions provide biological plausibility. No clinical PMS trials exist.
PMS symptoms including mood changes, bloating, and breast tenderness are associated with luteal-phase estrogen-progesterone imbalance. DIM is used in integrative practice to reduce estrogen dominance thought to drive PMS. A double-blind RCT of DIM for cervical abnormalities included PMS as a monitored sub-study endpoint, providing limited formal data.
Wild yam is used in herbal medicine for PMS symptoms including cramping, mood changes, and hormonal discomfort, owing to its antispasmodic and mild phytoestrogenic properties. This is a well-documented traditional use. Clinical evidence is absent.
Dong quai (Angelica sinensis) has been used in Traditional Chinese Medicine for over 2,000 years as a primary women's tonic for menstrual irregularity, PMS, dysmenorrhea, and amenorrhea. It is considered 'female ginseng' in TCM. However, no placebo-controlled RCTs specifically for PMS have been conducted.
Gamma-linolenic acid (GLA) is the active omega-6 fatty acid in evening primrose oil proposed to address a GLA deficiency contributing to PMS via prostaglandin E1 deficiency. Clinical RCT evidence via evening primrose oil is mixed to negative in most rigorous trials, though GLA remains widely recommended in complementary medicine for PMS.
Kava is used in herbal medicine for premenstrual tension, irritability, and cramping, extending from its documented anxiolytic, antispasmodic, and muscle-relaxant properties. The clinical herbalist literature and traditional Pacific use support this application. No dedicated RCT exists for kava in PMS specifically.
Lemon balm (Melissa officinalis) is used in European traditional medicine for anxiety, insomnia, and nervous complaints associated with PMS. Its rosmarinic acid and flavonoids inhibit GABA transaminase, increasing GABA levels. Small clinical studies support anxiolytic and mood-improving effects relevant to PMS symptoms.
Maca has a well-documented traditional use for PMS among Andean peoples, listed in ethnobotanical records and pharmacobotanical monographs. Clinical research on maca for PMS as a distinct condition is absent, though related effects on hormonal balance and mood in perimenopausal women have some scientific support.
Marjoram has a traditional reputation for relieving PMS symptoms including abdominal cramps, headache, and mood disturbance, attributed to its antispasmodic, analgesic, and nervine properties. Clinical documentation for PMS specifically is limited to traditional and anecdotal records.
Mugwort is documented in traditional Chinese medicine for premenstrual syndrome, and moxibustion has been studied in a clinical context for reducing premenstrual cramping. Adams et al. (Chinese Medicine, 2012) specifically reviewed mugwort for PMS treatment. Human evidence is from moxibustion applications rather than oral supplementation.
Passionflower (Passiflora incarnata) is used traditionally in Western and South American herbalism for anxiety, insomnia, and nervous tension associated with PMS. Its GABA-enhancing and MAO-inhibiting properties provide mechanistic support for its anxiolytic use in PMS-related mood symptoms.
Paeonia lactiflora is a central ingredient in TCM formulas for premenstrual syndrome, addressing symptoms such as irritability, abdominal pain, breast distension, and mood changes. Its antispasmodic, anti-inflammatory, and estrogenic activities provide mechanistic plausibility, but isolated clinical trial evidence is absent.
Red clover (Trifolium pratense) contains isoflavones—formononetin, biochanin A, daidzein, and genistein—that act as phytoestrogens. It has been traditionally used for menopausal and menstrual complaints including PMS, with some small clinical studies on menopausal symptoms and preliminary evidence from the broader phytoestrogen literature.
Royal jelly has been traditionally used in several cultures to reduce PMS symptoms including mood swings and bloating, attributed to its phytoestrogenic activity. It is a popular supplement among women for this purpose, but dedicated controlled clinical trials specifically targeting PMS as a primary endpoint are lacking.
Skullcap is documented in traditional practice for PMS and nervous tension associated with the menstrual cycle. Encyclopedia.com lists PMS among its contemporary herbal uses. Cherokee women used it for menstrual health, and its anxiolytic and antispasmodic properties address core PMS symptoms.
Traditional and naturopathic herbalism documents squawvine for PMS, particularly the type accompanied by water retention, pelvic congestion, and irritability. Its combined diuretic, uterine-tonic, and mild nervine properties are cited as the basis. No clinical trials exist.
Suma is used in traditional South American herbal practice to relieve PMS symptoms, attributed to its phytosterol and ecdysteroid content that may modulate estrogen and progesterone levels. This use is documented but unconfirmed by human clinical trials.
The NIH LiverTox database lists premenstrual syndrome among the conditions for which tribulus has historically been used. Traditional Ayurvedic use for fluid retention and menstrual discomfort aligns with PMS symptoms. No RCT has directly studied tribulus for PMS.
Wild yam (Dioscorea villosa) has historically been used for menstrual cramps and PMS in North American and eclectic herbal medicine. Its steroidal saponin diosgenin is a pharmaceutical precursor to progesterone, though the human body cannot perform this conversion. It is more commonly recommended for PMS in traditional contexts than supported by clinical trials.
Wood betony is listed in traditional herbal practice specifically for pre-menstrual complaints, combining its nervine and antispasmodic properties. It is documented in folk and herbal literature for frayed nerves, tension, and mood disturbance associated with the premenstrual phase.
Go back